GlassScriptPhysician profile
Merle L Wade
NPI 1033167465
$4,137.09
in general payments reported to CMS, 2019-2025
35 companies · $913 in 2025
The $913 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $464 · 2020: $230 · 2021: $679 · 2022: $819 · 2023: $515 · 2024: $517 · 2025: $913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,945.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,945.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $685.56 | 2019-2025 | Xtandi, Veozah |
| Sumitomo Pharma America, INC. | $638.10 | 2023-2025 | Gemtesa, Orgovyx |
| Endo Pharmaceuticals INC. | $346.18 | 2019-2024 | Xiaflex |
| Bayer Healthcare Pharmaceuticals INC. | $308.47 | 2019-2025 | |
| Pfizer INC. | $217.51 | 2019-2025 | |
| Janssen Biotech, INC. | $217.06 | 2022-2025 | Erleada |
| Axonics, INC. | $201.38 | 2020-2023 | Axonics, Bulkamid |
| Ferring Pharmaceuticals INC. | $164.37 | 2025 | Adstiladrin |
| Allergan, INC. | $161.58 | 2019-2022 | |
| Medtronic, INC. | $140.95 | 2021-2025 | Interstim |
| Coloplast Corp | $95.05 | 2019-2021 | |
| Ethicon US, LLC | $80.97 | 2021-2023 | Surgiflo Hemostatic Matrix, Echelon Flex |
| Boston Scientific Corporation | $77.59 | 2019-2025 | Spaceoar Vue System - 10ml, Axonics |
| Procept Biorobotics Corporation | $69.11 | 2023-2024 | Aquabeam System, Aquabeam Robotic System |
| Olympus America INC. | $66.30 | 2022-2025 | Itind System, Uretero-Reno Videoscope, Cysto-Nephro Videoscope |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $57.81 | 2021-2023 | Prolaris |
| Progenics Pharmaceuticals, INC. | $57.76 | 2023-2025 | Pylarify |
| Kerecis Limited | $54.43 | 2024-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Graftguide |
| Urovant Sciences INC | $51.99 | 2021-2022 | |
| Blue Earth Diagnostics | $48.60 | 2021-2025 | Posluma |
| Tolmar Pharmaceuticals, INC. | $46.76 | 2021-2022 | |
| Accord Healthcare, INC. | $42.88 | 2025 | |
| Urogen Pharma, INC. | $41.35 | 2025 | |
| Endo USA, INC. | $38.37 | 2024-2025 | Xiaflex |
| Abbvie INC. | $30.10 | 2019-2024 | |
| Hollister Incorporated | $27.88 | 2022 | |
| Dendreon Pharmaceuticals LLC | $24.97 | 2021 | |
| Therapeuticsmd, INC. | $24.69 | 2019 | |
| Travere Therapeutics, INC. | $22.75 | 2020-2021 | |
| Rochester Medical Corporation | $18.93 | 2021 | |
| Convatec INC. | $18.37 | 2020 | |
| Mission Pharmacal Company | $17.42 | 2019 | |
| Laborie Medical Technologies Corp. | $15.00 | 2025 | |
| Verity Pharmaceuticals INC. | $13.72 | 2025 | Trelstar |
| Photocure INC | $13.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Merle Wade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.